These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23226899)

  • 1. Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses.
    Moorthy VS; Hutubessy R; Newman RD; Hombach J
    Bull World Health Organ; 2012 Nov; 90(11):864-6. PubMed ID: 23226899
    [No Abstract]   [Full Text] [Related]  

  • 2. RTS,S malaria vaccine pilots in three African countries.
    Adepoju P
    Lancet; 2019 Apr; 393(10182):1685. PubMed ID: 31034365
    [No Abstract]   [Full Text] [Related]  

  • 3. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
    Kaslow DC; Biernaux S
    Vaccine; 2015 Dec; 33(52):7425-32. PubMed ID: 26431982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced purchase commitments for a malaria vaccine.
    Natl Bur Econ Res Bull Aging Health; 2005; (12):1-2. PubMed ID: 16175672
    [No Abstract]   [Full Text] [Related]  

  • 5. Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data.
    Galactionova K; Bertram M; Lauer J; Tediosi F
    Vaccine; 2015 Nov; 33(48):6710-8. PubMed ID: 26518406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policy challenges in malaria vaccine introduction.
    Moree M; Ewart S
    Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):248-52. PubMed ID: 15331844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
    Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effective analysis of childhood malaria vaccination in endemic hotspots of Bangladesh.
    Sarker AR; Sultana M
    PLoS One; 2020; 15(5):e0233902. PubMed ID: 32470101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evidence base on the cost-effectiveness of malaria control measures in Africa.
    Goodman CA; Mills AJ
    Health Policy Plan; 1999 Dec; 14(4):301-12. PubMed ID: 10787646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3: RTS,S almost halves malaria cases in young children.
    Riedmann EM
    Hum Vaccin Immunother; 2013 Dec; 9(12):2501. PubMed ID: 24716207
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania.
    Tediosi F; Hutton G; Maire N; Smith TA; Ross A; Tanner M
    Am J Trop Med Hyg; 2006 Aug; 75(2 Suppl):131-43. PubMed ID: 16931824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan.
    Gosling R; von Seidlein L
    PLoS Med; 2016 Apr; 13(4):e1001994. PubMed ID: 27070151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malaria vaccine development using synthetic peptides as a technical platform.
    Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
    Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Vaccines and Immunotherapeutics: News.
    Hum Vaccin Immunother; 2015; 11(6):1298. PubMed ID: 26086584
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccines against asexual stage malaria parasites.
    Kumar S; Epstein JE; Richie TL
    Chem Immunol; 2002; 80():262-86. PubMed ID: 12058644
    [No Abstract]   [Full Text] [Related]  

  • 16. The Economics of Malaria Vaccine Development.
    Plebanski M; Flanagan KL
    Trends Parasitol; 2017 Mar; 33(3):154-156. PubMed ID: 28169112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malaria vaccine trials.
    Greenwood B; Alonso P
    Chem Immunol; 2002; 80():366-95. PubMed ID: 12058650
    [No Abstract]   [Full Text] [Related]  

  • 18. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.
    Moorthy V; Reed Z; Smith PG;
    Vaccine; 2007 Jul; 25(28):5115-23. PubMed ID: 17577487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Vaccine Initiative: lessons from developing malaria vaccines.
    Geels MJ; Imoukhuede EB; Imbault N; van Schooten H; McWade T; Troye-Blomberg M; Dobbelaer R; Craig AG; Leroy O
    Expert Rev Vaccines; 2011 Dec; 10(12):1697-708. PubMed ID: 22085173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
    Vandoolaeghe P; Schuerman L
    Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.